Advertisement
Teleconference/Webcast Details
To participate in the live call on Monday, July 7, at 5:00 p.m. Easterntime by telephone, please dial 877-419-6590 from the U.S. or 719-325-4860internationally. A telephone replay will be available until July 9 atmidnight following the conclusion of the call by dialing 888-203-1112 from theU.S. or 719-457-0820 for international callers and entering passcode 4109873.Individuals interested in listening to the live call via webcast may do so byvisiting http://www.medivation.com. A replay of the webcast will be availableon the Company's website for 30 days.
Advertisement
About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapiddevelopment of novel small molecule drugs to treat serious diseases of thecentral nervous system and cancers for which there are limited treatmentoptions. Medivation aims to revolutionize the treatment of these diseases andoffer hope to critically ill patients and their caregivers. The Company'scurrent clinical development program includes a pivotal and confirmatory Phase3 trial of dimebon(TM) in Alzheimer's disease, a Phase 2 clinical trial ofdimebon in patients with Huntington's disease, and a Phase 1-2 clinical trialof MDV3100 in patients with castration-resistant (also known ashormone-refractory) prostate cancer. For more information, please visit us athttp://www.medivation.com.
This press release contains forward-looking statements, includingstatements regarding anticipated clinical and regulatory milestones, which aremade pursuant to the safe harbor provisions of the Private SecuritiesLitigation Reform Act of 1995. Forward-looking statements involve risks anduncertainties that could cause actual results to differ significantly fromthose projected. You are cautioned not to place undue reliance on theforward-looking statements, which speak only as of the date of this release.None of the Company's product candidates has been approved for sale,significant additional animal and human testing is required in order to seekmarketing approval for any of its product candidates, and Medivation cannotassure you that marketing approval can be obtained for any of its productcandidates. Furthermore, as is typically the case at this stage of theregulatory review process, the FDA has not yet performed an in-depth review ofMedivation's preclinical and clinical data, so its views remain subject tochange. Medivation's filings with the Securities and Exchange Commission,including its Annual Report on Form 10-KSB for the year ended December 31,2007 and its Quarterly Report on Form 10-Q for the quarter ended March 31,2008, include information about additional factors that could affect theCompany's financial and operating results.
SOURCE Medivation, Inc.
